Matthew O'Brien's Colleagues at Abeome Corporation
Matthew O'Brien's Contact Details
706-542-7889
Greater Atlanta Area
Abeome Corporation
Matthew O'Brien's Company Details
Abeome's DiSH technology is the key to driving unprecedented efficiencies in screening for new targets. Using DiSH, desired monoclonals can be identified using fluorescent-labeled antigens to bind surface-expressed antibodies, making isolation and cloning desired cells significantly easier. Abeome is actively looking for partners interested in leveraging the company's DiSH technology to enable accelerated pre-clinical identification and screening of monoclonal antibody targets. Our strategy encompasses licensing the platform technology to leading pharmaceutical/biotech companies, offering fee-for-service antibody generation, and co-developing our own mAbs for key therapeutic and diagnostic applications. Non-exclusive licenses are available for unlimited access and commercialization of the technology, or by specific fields of interest (i.e., research use only, diagnostics, animal health).